Payment overview · 2025
General Payments
$963.43
67 reported records · 12 companies
Healthcare provider profile · identity verified
William Andrew Mccormick, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BRISTOL, TN · NPI 1740411313
Verified facts
What the public records show
CMS Open Payments records show William Andrew Mccormick, M.D. received $963.43 in general payments during 2025 across 67 reported records.
Novartis Pharmaceuticals Corporation accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $380.11 | 39.5% | 25 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.61 | 16.9% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.73 | 16.5% | 9 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $52.65 | 5.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.60 | 4.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.74 | 4.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.72 | 3.1% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $20.75 | 2.1% | 3 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $19.63 | 2.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.05 | 1.8% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.18 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.66 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $963.43 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $380.11 | 25 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $162.61 | 18 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $148.49 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $142.11 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $142.11 | 8 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $52.65 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.17 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.71 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 204 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
204 | 40 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
255 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 637 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 558 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 124 |
| Losartan Potassium | Losartan Potassium | 465 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 463 | 129 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 415 | 84 |
| Furosemide | Furosemide | 398 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 378 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 98 |
| Omeprazole | Omeprazole | 314 | 93 |
| Alprazolam | Alprazolam | 281 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 278 | 95 |
| Famotidine | Famotidine | 270 | 72 |
| Eliquis | Apixaban | 255 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 247 | 48 |
| Lisinopril | Lisinopril | 226 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 211 | 62 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 210 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 204 | 40 |
| Metformin Hcl | Metformin Hcl | 201 | 52 |
| Meloxicam | Meloxicam | 191 | 47 |
| Prednisone | Prednisone | 186 | 101 |
| Glipizide Er | Glipizide | 177 | 43 |
| Allopurinol | Allopurinol | 175 | 47 |
| Trazodone Hcl | Trazodone Hcl | 174 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 29 |
| Carvedilol | Carvedilol | 169 | 43 |
| Montelukast Sodium | Montelukast Sodium | 169 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 150 | 25 |
| Celecoxib | Celecoxib | 145 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 39 |
| Sertraline Hcl | Sertraline Hcl | 139 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 134 | 31 |
| Tramadol Hcl | Tramadol Hcl | 129 | 30 |
| Metformin Hcl Er | Metformin Hcl | 126 | 27 |
| Clonazepam | Clonazepam | 123 | 14 |
| Nitroglycerin | Nitroglycerin | 121 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 111 | 33 |
| Potassium Chloride | Potassium Chloride | 111 | 28 |
| Promethazine Hcl | Promethazine Hcl | 102 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 25 |
| Methocarbamol | Methocarbamol | 89 | 35 |
| Simvastatin | Simvastatin | 87 | 28 |
| Pregabalin | Pregabalin | 86 | 17 |
| Sucralfate | Sucralfate | 85 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 26 |
| Jardiance | Empagliflozin | 82 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 49 |
| Finasteride | Finasteride | 76 | 17 |
| Ozempic | Semaglutide | 73 | 16 |
| Azithromycin | Azithromycin | 72 | 60 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 17 |
| Mounjaro | Tirzepatide | 68 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 15 |
| Estradiol | Estradiol | 67 | 12 |
| Topiramate | Topiramate | 66 | 14 |
| Fluconazole | Fluconazole | 65 | 29 |
| Ibuprofen | Ibuprofen | 62 | 20 |
| Valsartan | Valsartan | 61 | 18 |
| Glipizide | Glipizide | 60 | 21 |
| Mirtazapine | Mirtazapine | 59 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | suppressed |
| Spironolactone | Spironolactone | 57 | 21 |
| Bupropion Xl | Bupropion Hcl | 56 | 16 |
| Buspirone Hcl | Buspirone Hcl | 56 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 16 |
| Xarelto | Rivaroxaban | 56 | 11 |
| Aripiprazole | Aripiprazole | 54 | suppressed |
| Atenolol | Atenolol | 54 | 15 |
| Ondansetron Odt | Ondansetron | 52 | 12 |
| Lorazepam | Lorazepam | 50 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 11 |
| Farxiga | Dapagliflozin Propanediol | 49 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 11 |
| Diazepam | Diazepam | 47 | suppressed |
| Eszopiclone | Eszopiclone | 47 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 12 |
| Donepezil Hcl | Donepezil Hcl | 46 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 16 |
| Ezetimibe | Ezetimibe | 45 | 15 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Cephalexin | Cephalexin | 36 | 15 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Nystatin | Nystatin | 33 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 11 |
| Temazepam | Temazepam | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Mupirocin | Mupirocin | 31 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Roflumilast | Roflumilast | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 20 |
| Torsemide | Torsemide | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Amoxicillin | Amoxicillin | 19 | 15 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Benzonatate | Benzonatate | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Sumatriptan | Sumatriptan | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $963.43 · 67 records | Novartis Pharmaceuticals Corporation | AREXVY, Auvelity, ETERNA, General - Erectile Dysfunction, Heplisav-B, LEQVIO, NURTEC ODT, Natroba, Ozempic, QULIPTA, Rybelsus, SHINGRIX, Spinosad, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error